Furthermore, recurrent focal chromosome amplifications in CCND1, FGF19, VEGFA, MYC, or MET genes, as well as changes in epigenetic regulation, oxidative stress, and the AKT–mTOR and MAPK pathways have been reported in HCC [26, 27]. This evidence concerns the gene MET and hepatocellular carcinoma.